GMAB
Income statement / Annual
Last year (2023), Genmab A/S's total revenue was $16.47 B,
an increase of 12.87% from the previous year.
In 2023, Genmab A/S's net income was $4.35 B.
See Genmab A/S’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$16.47 B
|
$14.60 B
|
$8.48 B
|
$10.11 B
|
$5.37 B
|
$3.03 B
|
$2.37 B
|
$1.82 B
|
$1.13 B
|
$850.39 M
|
Cost of Revenue |
$553.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
$15.92 B |
$14.60 B |
$8.48 B |
$10.11 B |
$5.37 B |
$3.03 B |
$2.37 B |
$1.82 B |
$1.13 B |
$850.39 M |
Gross Profit Ratio |
0.97 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Research and Development
Expenses |
$7.44 B
|
$5.56 B
|
$4.18 B
|
$3.14 B
|
$2.39 B
|
$1.43 B
|
$874.28 M
|
$660.88 M
|
$487.66 M
|
$505.68 M
|
General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$661.00 M
|
$342.00 M
|
$213.70 M
|
$146.99 M
|
$102.41 M
|
$91.22 M
|
$79.53 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$3.17 B
|
$2.68 B
|
$1.28 B
|
$661.00 M
|
$342.00 M
|
$213.70 M
|
$146.99 M
|
$102.41 M
|
$91.22 M
|
$79.53 M
|
Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$176.22 M |
$0.00 |
Operating Expenses |
$10.60 B |
$8.24 B |
$5.46 B |
$3.80 B |
$2.73 B |
$1.64 B |
$1.02 B |
$763.29 M |
$402.66 M |
$585.21 M |
Cost And Expenses |
$11.15 B |
$8.24 B |
$5.46 B |
$3.80 B |
$2.73 B |
$1.64 B |
$1.02 B |
$763.29 M |
$402.66 M |
$585.21 M |
Interest Income |
$939.00 M |
$324.00 M |
$197.00 M |
$184.00 M |
$120.00 M |
$62.92 M |
$41.43 M |
$32.58 M |
$37.26 M |
$38.33 M |
Interest Expense |
$27.00 M |
$21.00 M |
$13.00 M |
$10.00 M |
$7.00 M |
$417,000.00 |
$2.80 M |
$213,000.00 |
$118,000.00 |
$4.05 M |
Depreciation &
Amortization |
$327.00 M
|
$290.00 M
|
$250.00 M
|
$246.00 M
|
$139.00 M
|
$87.70 M
|
$47.54 M
|
$40.96 M
|
$31.82 M
|
$12.33 M
|
EBITDA |
$5.65 B
|
$7.04 B
|
$3.46 B
|
$6.76 B
|
$2.90 B
|
$1.70 B
|
$1.14 B
|
$1.17 B
|
$789.47 M
|
$313.73 M
|
EBITDA Ratio |
0.34 |
0.48 |
0.41 |
0.67 |
0.54 |
0.56 |
0.48 |
0.64 |
0.7 |
0.37 |
Operating Income Ratio
|
0.32
|
0.44
|
0.36
|
0.62
|
0.49
|
0.46
|
0.57
|
0.58
|
0.64
|
0.31
|
Total Other
Income/Expenses Net |
$316.00 M
|
$678.00 M
|
$965.00 M
|
-$409.00 M
|
$221.00 M
|
$231.69 M
|
-$280.45 M
|
$77.38 M
|
$27.15 M
|
$32.17 M
|
Income Before Tax |
$5.64 B |
$7.04 B |
$3.98 B |
$5.90 B |
$2.86 B |
$1.61 B |
$1.06 B |
$1.13 B |
$757.53 M |
$297.35 M |
Income Before Tax Ratio
|
0.34
|
0.48
|
0.47
|
0.58
|
0.53
|
0.53
|
0.45
|
0.62
|
0.67
|
0.35
|
Income Tax Expense |
$1.29 B |
$1.51 B |
$975.00 M |
$1.15 B |
$693.00 M |
$139.83 M |
-$39.83 M |
-$56.86 M |
-$5.99 M |
-$3.95 M |
Net Income |
$4.35 B |
$5.45 B |
$2.96 B |
$4.76 B |
$2.17 B |
$1.47 B |
$1.10 B |
$1.19 B |
$763.51 M |
$301.30 M |
Net Income Ratio |
0.26 |
0.37 |
0.35 |
0.47 |
0.4 |
0.49 |
0.47 |
0.65 |
0.67 |
0.35 |
EPS |
6.66 |
8.34 |
4.52 |
7.3 |
3.44 |
2.4 |
1.81 |
1.98 |
1.31 |
0.54 |
EPS Diluted |
6.6 |
8.26 |
4.48 |
7.22 |
3.4 |
2.37 |
1.78 |
1.92 |
1.26 |
0.53 |
Weighted Average Shares
Out |
$653.10 M
|
$653.87 M
|
$653.96 M
|
$651.79 M
|
$629.63 M
|
$612.68 M
|
$608.34 M
|
$598.76 M
|
$585.21 M
|
$563.15 M
|
Weighted Average Shares
Out Diluted |
$659.15 M
|
$660.10 M
|
$660.46 M
|
$658.86 M
|
$636.37 M
|
$620.45 M
|
$620.94 M
|
$617.66 M
|
$607.74 M
|
$572.51 M
|
Link |
|
|
|
|
|
|
|
|
|
|